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Formation of compact and poorly lysable clots has been reported in thromboembolic disor-
ders. Little is known about clot properties in bleeding disorders.
Objectives
We hypothesized that more permeable and lysis-sensitive fibrin clots can be detected in
women with heavy menstrual bleeding (HMB).
Methods
We studied 52 women with HMB of unknown cause and 52 age-matched control women.
Plasma clot permeability (Ks), turbidity and efficiency of fibrinolysis, together with coagula-
tion factors, fibrinolysis proteins, and platelet aggregation were measured.
Results
Women with HMB formed looser plasma fibrin clots (+16% [95%CI 7–18%] Ks) that dis-
played lower maximum absorbancy (-7% [95%CI -9 – -1%] ΔAbsmax), and shorter clot lysis
time (-17% [95%CI -23 – -11%] CLT). The HMB patients and controls did not differ with re-
gard to coagulation factors, fibrinogen, von Willebrand antigen, thrombin generation mark-
ers and the proportion of subjects with defective platelet aggregation. The patients had
lower platelet count (-12% [95%CI -19 – -2%]), tissue plasminogen activator antigen (-39%
[95%CI -41 – -29%] tPA:Ag), and plasminogen activator inhibitor-1 antigen (-28% [95%CI
-38 – -18%] PAI-1:Ag) compared with the controls. Multiple regression analysis upon adjust-
ment for age, body mass index, glucose, and fibrinogen showed that decreased tPA:Ag and
shortened CLT were the independent predictors of HMB.
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Conclusions
Increased clot permeability and susceptibility to fibrinolysis are associated with HMB, sug-
gesting that altered plasma fibrin clot properties might contribute to bleeding disorders of
unknown origin.
Introduction
Heavy menstrual bleeding (HMB), that occurs at normal intervals (21–35 days) but lasts longer
than 7 days or is associated with blood loss of more than 80 ml, affects 5% of the population of
women mostly in reproductive age [1–2]. Over a half of the patients with HMB do not manifest
any organic pathology. HMB is responsible for iron deficiency in women and lowers their qual-
ity of life [3]. A number of known causes of HMB have been identified, including several hemo-
static disorders, particularly von Willebrand disease (VWD) that occurs in 5–20% of patients
with HMB as compared with less than 1% of women with normal menstruation [4]. Other
known pathologies underlying HMB are: inherited bleeding disorders (e.g. haemophilia), endo-
metrial polyps or carcinoma, use of contraceptive pills or hormonal therapy, diet changes,
treatment with anticoagulants, antiplatelet agents or certain drugs (e.g. steroids), and gestation-
al complications (e.g. miscarriages) [5–7]. The first study of haemostasis in patients with HMB
was published about 20 years ago [8], however little is known about clot properties in HMB.
There is growing evidence that plasma fibrin clots composed of compact networks with thin
fibers that are less susceptible to lysis [9] can be observed in patients with a history of myocar-
dial infarction [10], ischemic stroke [11], and peripheral artery disease [12]. It is unclear wheth-
er specific abnormalities in plasma fibrin clot properties can be detected in patients with
bleeding tendency. Haemophilia A and B have been shown to be characterized by delayed and
slower production of fibrin with the subsequent formation of plasma fibrin clots composed of
thick fibrin fibres with larger pores that are more susceptible to lysis [13]. These abnormalities
have been postulated to be largely caused by reduced thrombin generation in haemophilia [13].
Furthermore, some congenital dysfibrinogenemias could be associated with HMB, e.g. in the fi-
brinogen AαIVS4+1G>T heterozygous mutation with the Aα4841delC mutation in the other
allele [14].
Plasma fibrin clot formation and structural characteristics in subjects with HMB of un-
known origin have not been reported yet. We hypothesized that such women with HMB have
abnormal plasma fibrin clot properties including increased clot permeability and lysability. We




Of the 130 screened women, we examined 52 consecutive women aged 50 years or less diag-
nosed with HMB who were referred by gynecologists to the Center for Coagulation Disorders
for further laboratory work-up between January 2009 and June 2012. Fifty-two age-and
weight-matched (by frequency) apparently healthy women with a subjectively normal men-
struation, recruited among the hospital personnel and relatives (n = 88), served as controls.
The 36 healthy control women were excluded from the study due to the use of progestogens or
combined oral contraceptives, intrauterine devices or other medications, in particular aspirin
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or other nonsteroidal anti-inflammatory agents. All patients with HMB had a history of heavy,
regular menstrual periods, defined on the basis of the scoring system of Higham et al. [15]. The
exclusion criteria were uterine pathologies including polyps, fibroid tumours, endometritis;
known hematologic disorders, including VWD and deficiencies of coagulation factors; the use
of nonsteroidal anti-inflammatory agents (in particular aspirin), antifibrinolytics or anticoagu-
lants; platelet count below 100 G/l; sideropenic anemia; acute infections or severe comorbidi-
ties (e.g. malignancy, renal insufficiency). Only women who did not take progestogens or
combined oral contraceptives and could not use of intrauterine devices in the previous 3
months were eligible. All the individuals declared not taking any medications within the 2
weeks prior to enrollment. Iron replacement therapy within the previous 6 months was re-
ported by 28 women. We recorded bleeding episodes based on medical records and self-
declared signs and symptoms such as epistaxis, easy bruising, gingival bleeding and gastrointes-
tinal bleeding in the past. Family history of bleeding was arbitrarily defined as self-reported
easy bruising or other bleeding tendency in any family member including first and second de-
gree relatives. The Bioethics Committee of the Jagiellonian University approved the study. All
the subjects signed written informed consent.
Laboratory investigations
Fasting blood was drawn from an antecubital vein with minimal stasis within the first 10 days
after menstruation. Plasma samples (9:1 of 3.2% trisodium citrate) for fibrin clot assays were
centrifuged (20 min, 2500 g) within 30 minutes of collection to obtain platelet-poor plasma,
immediately frozen, and stored in aliquots at—80°C. Lipid profiles, blood cell counts, glucose,
creatinine, D-dimer, international normalized ratio (INR), and activated partial thromboplas-
tin time (APTT) were assayed by routine laboratory techniques. Serum ferritin was measured
by the latex-enhanced immunoturbidimetry (Roche Diagnostics, Mannheim, Germany). Fi-
brinogen was determined using the von Clauss method. High-sensitivity C-reactive protein
(CRP) was measured by latex nephelometry (Siemens). Factor (F)II, FV, FVII, FVIII, FIX, and
FX were measured by one-stage clotting assays using factor-deficient plasma (Siemens, Mar-
burg, Germany). FXIII activity was determined by the chromogenic assay (Siemens, Marburg,
Germany). All patients had coagulation factors above 70% of the reference range. VWF antigen
(vWF:Ag) was measured by latex immunoassay on a STAR coagulation instrument (Diagnos-
tica Stago, Asnieres, France). All patients had vWF:Ag above 50 IU/dL. Tissue-type plasmino-
gen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) antigens and plasmin-alpha
2-antiplasmin complexes (PAP) were measured by enzyme-linked immunoabsorbent assays
(ELISAs) (all, American Diagnostica, Stamford, CT). The interassay and intraassay coefficients
of variation for the ELISAs were<8%.
Platelet aggregation
Platelet function was assessed by means of aggregometry as described [16]. The citrated blood
samples were centrifuged at 120 g for 10 min for platelet-rich plasma and then at 850 g for 10
min for platelet-poor plasma. Platelet reactivity was evaluated in platelet-rich plasma for 6
minutes at 37°C using the light transmittance aggregometer (Chrono-Log Corp., Haverton,
PA) after stimulation with 5 μM adenosine diphosphate (ADP). Maximal platelet aggregation
after stimulation was expressed as the maximal percent change in light transmittance in plate-
let-rich plasma from baseline, using platelet-poor plasma as a reference. Defective aggregation
was defined as a maximal values below 75% of the reference values.
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Clot permeability
Permeation of plasma fibrin clots was determined as described [17–19]. Plasma was diluted
1:1. Briefly, 20 mM calcium chloride and 1 U/mL human thrombin (Sigma) were added to
citrated plasma. Tubes containing the clots were connected to a reservoir of a Tris-buffered sa-
line (TBS) buffer (0.01 M Tris, 0.1 M NaCl, pH 7.5), and its volume flowing through the gels
was measured within 60 minutes. A permeation coefficient (Ks), which indicates the pore size,
was calculated from the equation: Ks = QxLxη/txAxΔp, where Q is the flow rate in time t, L is
the length of a fibrin gel, η is the viscosity of liquid (in poise), t is percolating time, A is the
cross-sectional area (in cm2), and Δp is a differential pressure (in dyne/cm2). The interassay
variability was 7.4%.
Turbidity measurements
Plasma samples were diluted 1:1 with a buffer (0.05 M Tris-HCl, 0.15 MNaCl, pH 7.4) contain-
ing 1 U/mL human thrombin (Sigma) and 15 mM calcium chloride to start fibrin polymeriza-
tion [16,17]. Absorbance was read at 405 nm for 15 minutes with a Perkin-Elmer Lambda 4B
spectrophotometer (Molecular Devices Corp). The lag phase of the turbidity curve is the time
required for fibrin protofibrils to grow to sufficient length to allow lateral aggregation to occur.
Maximum absorbance at plateau (ΔAbsmax) reflects the number of protofibrils per fiber. The
interassay and intraassay coefficients of variation were<7%.
Clot lysis assays
Assay 1. In the first assay, clot lysis time (CLT) was measured using the turbidity method of
Lisman et al. with a slight modification [19] Briefly, plasma was mixed with 15 mM calcium
chloride, 10000-diluted human 0.6 pM tissue factor (Innovin, Dade Behring), 12 μM phospho-
lipid vesicles and 60 ng/mL recombinant tPA (Boehringer Ingelheim, Germany). Measure-
ments were performed at 405 nm at 37 °C. Clot lysis time was defined as the time from the
midpoint of the clear-to-maximum-turbid transition, which represents clot formation, to the
midpoint of the maximum-turbid-to-clear transition.
Assay 2. Plasma fibrin clots formed as described in the permeability assay were perfused
with the same buffer containing 0.2 μM recombinant tPA [18,20]. The lysis rate was deter-
mined by measuring the concentration of D-dimer (American Diagnostica), a marker of plas-
min-mediated fibrin degradation, every 15 minutes in the effluent. Maximum rates of increase
in D-dimer levels (D-Drate, mg/L/min) was analyzed in each subject. The experiment was
stopped when the fibrin gel collapsed. The interassay coefficients of variation for lysis variables
were<7%.
Thrombin Generation Potential
To assess plasma thrombogenic potential, the thrombogram was analyzed using the CAT
(Thrombinoscope BV, Maastricht, the Netherlands) according to the manufacturer’s instruc-
tions in the 96-well plate fluorometer (Ascent Reader, Thermolabsystems OY, Helsinki, Fin-
land) equipped with the 390/460 filter set at a temperature of 37°C. Eighty microliters of
platelet-poor plasma was diluted with 20 μL of the reagent containing 5 pmol/L recombinant
tissue factor, 4 micromolar phosphatidylserine/phosphatidylcholine/phosphatidylethanol-
amine vesicles, and 20 μL of FluCa solution (Hepes, pH 7.35, 100 nmol/L CaCl2, 60 mg/mL bo-
vine albumin, and 2.5 mmol/L Z-Gly-Gly-Arg-amido methyl coumarin). Each plasma sample
was analyzed in duplicate, and the intraassay variability was 6%. For analysis, the maximum
concentration of thrombin generated and Endogenous Thrombin Potential (ETP) were used.
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Scanning electron microscopy (SEM)
Plasma fibrin clots from randomly selected patients and controls were analyzed. Fixation was
performed after the permeability measurement with the use of 2.5% of glutaraldehyde in phos-
phate-buffered saline solution for 2 hours. Fixed clots were gently removed from tubes, washed
with distilled water, and then dehydrated in graded water-ethanol solutions, dried by the criti-
cal point procedure, and sputter coated with gold. Samples were scanned in six different areas
(microscope JEOL JCM-6000; JEOL Ltd., Tokyo, Japan).
Statistical analysis
The data are shown as median (range), mean ± standard deviation (SD), or percentage as ap-
propriate. Continuous variables were first checked for normal distribution by the Shapiro-Wilk
test. The Mann-Whitney U or Student tests were used as appropriate. The χ2 test was used to
compare the category frequencies. The Pearson or Spearman rank correlation coefficients were
calculated to test the association between 2 variables with a normal or non-normal distribution,
respectively. The relative risk of HMB associated with Ks, CLT and lag phase was estimated as
an odds ratio (OR) and corresponding 95% confidence interval (CI) using logistic regression,
adjusted for age, body mass index (BMI), glucose, and fibrinogen. Percentiles (70th, 80th, 90th,
and 95th) of the Ks, and CLT measured in the control group were used as the cut-off levels. All
clinical and angiographic variables that showed the association with HMB were then included
in the stepwise multiple logistic regression analysis. P< 0.05 was considered statistically signifi-
cant. Variables were standardized to age, BMI, fibrinogen and glucose. Independent predictors
of HMB were evaluated using Receiver Operating Curve (ROC) analysis. The cut-off values
were calculated by using the Youden index.
The study was powered to have a 90% chance of detecting a 10% difference in CLT using a
P value of 0.01, based on the values of CLT in the published article [21]. In order to demon-
strate such a difference or greater, 32 patients were required in each group.
Results
The patient and control groups were matched for age, BMI, and the prevalence of current
smoking (Table 1). Bleeding tendency manifestations, including easy bruising, were self-re-
ported in similar proportions of the subjects in both groups (Table 1). Women with HMB had
normal, but slightly lower platelet count (by 12%) with similar proportions of subjects with de-
fective platelet aggregation compared with the controls (Table 1). Ferritin, APTT and vWF:Ag
levels did not differ between the groups (Table 1). Coagulation factors, including fibrinogen, as
well as routine coagulation tests and D-dimer were similar in both groups (Tables 1 and 2). Of
note, patients with HMB had lower tPA:Ag and PAI-1:Ag with a positive association (r = 0.52;
P = 0.01) between these two variables (Table 3). Women with HMB had 7.5% higher PAP com-
pared with the controls (Table 1). ETP and the maximum concentration of thrombin generated
were similar in both groups (Table 3).
Clot permeability
Plasma fibrin clots from the HMB patients were more permeable than those from the controls
(Table 3). Ks was associated with fibrinogen (r = -0.52), D-dimer (r = -0.30), APTT (r = 0.33),
and tPA:Ag (r = -0.39; all P< 0.05). There were no correlations between Ks and duration of the
period or the presence of other bleeding manifestations (data not shown). Multiple regression
analysis adjusted for age, BMI, fibrinogen, and glucose showed that Ks was independently asso-
ciated with the length of a cycle alone (R2 = 0.49, P = 0.02; β = 0.32, 95% CI: 0.29–0.35) in the
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HMB patients. To investigate the potential contribution of Ks to the presence of HMB, different
cut-off levels were set according to the 70th, 80th, 90th, and 95th percentiles (Table 4).
Turbidity measurements
Compared with control subjects, HMB patients had slightly altered turbidimetric curves
(Table 3). The lag phase was correlated with age at the onset of HMB (r = 0.33), duration of the
period (r = 0.40), and tPA:Ag (r = -0.44; all P< 0.05). In the patient group ΔAbsmax correlated
with fibrinogen (r = 0.43; P< 0.05). Multiple regression analysis adjusted for age, BMI, fibrino-
gen, and glucose showed that the lag phase was independently associated with age at the onset
Table 1. Characteristics of patients with heavymenstrual bleeding and controls.
Variables Patients (n = 52) Control subjects (n = 52) P value
Age, ya 36 (29–44) 39 (30–45) 0.49
BMI, kg/m2a 25.7 (24.0–29.5) 25.1 (23.8–27.4) 0.30
Length of cycle, da 27 (24–31) 26 (24–29) 0.38
Duration of period, da 9 (8–12) 6 (4–7) < 0.001
Hemoglobin, g/dLa 13.4 (12.4–14.3) 13.9 (12.7–14.7) 0.23
Platelets, x103/μLa 219.5 (196.5–264.5) 249.5 (205.0–290.0) 0.02
Total cholesterol, mMa 5.20 (4.23–5.77) 4.93 (4.22–5.62) 0.55
LDL cholesterol, mMa 2.97 (2.36–3.33) 2.99 (2.50–3.50) 0.65
HDL cholesterol, mMa 1.54 (1.16–1.72) 1.39 (1.13–1.72) 0.46
Triglycerides, mMa 1.17 (0.67–1.58) 1.02 (0.70–1.53) 0.89
Glucose, mMa 4.9 (4.5–5.1) 4.6 (4.3–5.1) 0.12
Creatinine, μMb 67.9 ± 15.6 68.4 ± 8.4 0.86
hsCRP, mg/La 1.35 (0.80–2.22) 1.77 (1.01–2.39) 0.77
INRa 1.00 (0.92–1.06) 0.98 (0.91–1.05) 0.57
APTT, sa 28.7 (26.9–30.9) 28.9 (27.4–30.9) 0.79
Fibrinogen, g/La 2.5 (2.3–2.7) 2.6 (2.3–3.2) 0.26
D-dimer, mg/dLb 247 ± 10 256 ± 14 0.58
tPA:Ag, ng/mLa 5.96 (5.11–7.02) 9.72 (8.65–10.88) < 0.001
PAI-1:Ag, ng/mLb 8.54 ± 1.85 11.89 ± 3.84 < 0.001
PAP, μg/La 232.0 (202.0–283.5) 214.5 (167.5–257.0) 0.04
Ferritin, ng/mLa 68.8 (17.2–115.2) 47.3 (18.9–146.6) 0.40
vWF:Ag, IU/dLa 99.0 (89.0–108.0) 99.5 (91.5–108.5) 0.70
Age at onset of heavy menstrual bleeding, ya 18 (16–26) - -
Current smokers, n (%)c 12 (23) 12 (23) 1.00
Family history, n (%)c 8 (15) 11 (21) 0.45
Bruising, n (%)c 11 (21) 9 (17) 0.61
Epistaxis, n (%)c 6 (12) 3 (6) 0.29
Severe bleeds, n (%)c 2 (4) 0 (0) 0.15
Defective aggregation, n (%)c 12 (23) 16 (31) 0.38
BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; INR, international
normalized ratio; APTT, activated partial thromboplastin time; tPA:Ag, tissue plasminogen activator antigen; PAI- 1:Ag, plasminogen activator inhibitor-1
antigen; PAP, plasmin-alpha 2-antiplasmin complexes; vWF:Ag, von Willebrand factor antigen.
aData are shown as median (interquartile range); Comparison between 2 groups using the Mann Whitney U test;
bData are shown as mean ± standard deviation; Comparison between 2 groups using the Student t-test;
cComparison between 2 groups using χ2 test.
doi:10.1371/journal.pone.0125069.t001
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of HMB (R2 = 0.45, P = 0.01; β = 0.54, 95% CI: 0.49–0.58), while we identified no independent
predictors of ΔAbsmax.
Clot lysis
CLT was shorter in women with HMB compared with controls (Table 3). In these patients,
CLT was inversely correlated with hemoglobin (r = -0.36), PAP (r = -0.50) and positively asso-
ciated with fibrinogen (r = 0.35), and FX (r = 0.34; all P< 0.05), but not with PAI-1:Ag. There
were also no associations with CLT and either the length of the cycle or duration of the period
(data not shown). Multiple regression analysis adjusted for age, BMI, fibrinogen, and glucose
showed that CLT was independently associated only with tPA:Ag (R2 = 0.41, P = 0.014; β =
0.24, 95% CI: 0.21–0.27) in the HMB patients. To investigate the potential contribution of CLT
to the presence of HMB, different cut-off levels were set, according to the 70th, 80th, 90th, and
95th percentiles (Table 5). Time-courses of the D-dimer release from plasma fibrin clots dem-
onstrated that D-Drate in this assay did not differ between the groups (Table 3). D-Drate was
correlated with duration of the period (r = -0.35), and D-dimer (r = 0.36; all P< 0.05). Multiple
regression analysis adjusted for age, BMI, fibrinogen, and glucose showed that the D-Drate was
independently associated only with VWF:Ag (R2 = 0.45, P = 0.02; β = 0.39, 95% CI: 0.34–0.43)
Table 2. Coagulation factors in patients with heavymenstrual bleeding and controls.
Coagulation factor Patients (n = 52) Control subjects (n = 52) P value
FII (IU/dL) 103.8 (94.3–117.1) 107.2 (93.2–122.1) 0.37
FV (IU/dL) 100.5 (86.5–109.5) 96.4 (83.3–105.6) 0.21
FVII (IU/dL) 101.0 (95.6–108.2) 103.2 (92.4–111.1) 0.94
FVIII (IU/dL) 113.3 (88.7–131.6) 116.7 (101.5–128.7) 0.43
FIX (IU/dL) 102.2 (95.0–112.0) 100.0 (89.0–108.1) 0.10
FX (IU/dL) 101.5 (94.7–111.0) 99.1 (87.8–111.7) 0.37
FXI (IU/dL) 101.5 (94.0–110.0) 100.2 (86.1–111.4) 0.26
FXIII (%) 101.3 ± 10.0 101.0 ± 9.2 0.82
F, factor.
Data are shown as median (interquartile range) or mean ± standard deviation (for FXIII); Comparison between 2 groups using Mann Whitney U test or
Student t-test.
doi:10.1371/journal.pone.0125069.t002
Table 3. Comparisons of fibrin clot variables and thrombin generation parameters in patients with heavymenstrual bleeding and controls.
Variables Patients (n = 52) Control subjects (n = 52) P value
Ks (10
–9 cm2) a 8.9 (7.8–9.4) 7.5 (7.0–8.1) < 0.001
Lag phase (s) a 45 (42–49) 43 (40–46) 0.05
ΔAbsmax (405 nm)
a 0.75 (0.73–0.84) 0.81 (0.77–0.87) 0.02
CLT (min) b 66.5 ± 11.9 80.6 ± 12.7 < 0.001
D-Drate (mg/L/min)
a 0.072 (0.070–0.077) 0.072 (0.068–0.079) 0.60
ETP (nM x min) a 1241 (1185–1368) 1290 (1148–1437) 0.40
Peak thrombin generation (nM) a 206 (169–272) 239 (198–271) 0.24
Ks, permeability coefficient; ΔAbsmax (405 nm), maximum absorbancy of a fibrin gel at 405 nm; CLT, clot lysis time; D-Drate, maximum rate of increase in
D-dimer levels; ETP, endogenous thrombin potential; Peak thrombin generation, maximum concentration of thrombin generated.
aData are shown as median (interquartile range); Comparison of subjects between 2 groups with analysis of Mann Whitney U test;
bData are shown as mean ± standard deviation; Comparison of subjects between 2 groups with analysis of Student test.
doi:10.1371/journal.pone.0125069.t003
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and FXI (R2 = 0.44, P = 0.04; β = -0.39, 95% CI: −0.44- −0.34), respectively, in the HMB
patients.
Regression and ROC analysis
Variables such as age, BMI, glucose, and fibrinogen were used for standardization. Multivariate
model of stepwise multiple logistic regression analysis, including all the subjects studied
(n = 104), showed that tPA:Ag and CLT were the only independent predictors of HMB. After ad-
justing for age, BMI, glucose, and fibrinogen, ORs were 0.38 (95% CI 0.26–0.56; P< 0.001) for
tPA:Ag (per 1 ng/mL) and 0.93 (95% CI 0.88–0.98; P = 0.014) for CLT (per 1 min). As shown in
Figs 1 and 2, the highest area under the curve (AUC) was found for tPA:Ag (AUC = 0.906, 95%
CI = 0.843–0.968, cut-off = 7.74 ng/mL, sensitivity = 0.885, specificity = 0.875), while AUC for
CLT was 0.800 (95%CI = 0.717–0.884, cut-off = 66 min, sensitivity = 0.615, specificity = 0.865).
Clot structure
Representative SEM images (Fig 3) showed that the plasma clots from the HMB patients were
composed of more loosely packed fibrin fibres than those from the healthy controls.
Discussion
The current study demonstrates that abnormal plasma fibrin clot properties, including forma-
tion of less compact fibrin networks displaying faster lysability, occur in women with heavy
prolonged menstrual bleeding which cause cannot be identified. To our knowledge, this study
is the first to show that slightly, though significantly increased plasma clot permeability in
women with HMB. Our findings show that abnormal structure and function of fibrin network
are involved not only in thrombotic disorders [9–12], but also in such common bleeding disor-
ders as HMB in women free of known deficiencies in coagulation factors, thrombocytopenia,
VWD or other hemorrhagic diatheses. Since the proper balance between fibrin formation and
degradation is necessary to protect the vascular system from excess blood loss, our findings in-
dicate that formation of looser clots sensitive to tPA-mediated lysis might contribute to HMB.
Table 4. Risk of heavymenstrual bleeding according to permeability coefficient (Ks).
Cut-off percentile Cut-off Ks, 10
–9 cm2 No. of controls No. of cases OR (95% CI) a P value
70 8.0 8 29 9.27 (3.16–27.2) < 0.001
80 8.3 7 21 4.73 (1.62–13.9) 0.005
90 9.5 6 12 2.02 (0.64–6.41) 0.232
95 9.6 4 9 2.21 (0.60–8.13) 0.234
a Odds ratios (ORs) adjusted for age, BMI, glucose and fibrinogen; CI, confidence interval.
doi:10.1371/journal.pone.0125069.t004
Table 5. Risk of heavymenstrual bleeding according to clot lysis time (CLT).
Cut-off percentile Cut-off CLT, min No. of controls No. of cases OR (95% CI) a P value
70 89 27 10 0.22 (0.09–0.54) 0.001
80 95 21 7 0.23 (0.08–0.63) 0.004
90 99 15 3 0.15 (0.03–0.54) 0.005
95 100 12 1 0.05 (0.01–0.45) 0.008
a ORs adjusted for age, BMI, glucose and fibrinogen. Abbreviations: see Table 4.
doi:10.1371/journal.pone.0125069.t005
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Very recently, Wiewel-Verschueren et al. [22] have compared clot lysis time in 102 women
with HMB versus 28 healthy controls, and they did not observe lower values in the former
group. The reasons for the discrepant results of that and our study are likely associated with
different patient characteristics and different selection methods of patients. In contrast to the
our study, Wiewel-Verschueren et al. [22] did not exclude women with gynaecological abnor-
malities (present in 33% of the patients, no data for controls) and studied also female patients
mostly above 40 years of age, with low haemoglobin and ferritin.
We analyzed several factors that might be implicated in unfavorable plasma fibrin clot fea-
tures in women with HMB. Since fibrinogen, a key modulator in fibrin properties [9,23], was
similar in both groups, the intergroup differences in plasma fibrin clot parameters cannot be
explained by any differences in the fibrinogen concentration. A modulatory role of factors II,
V,VII, IX, X and XI, which plasma levels were similar and within the reference ranges in the pa-
tients and controls, is of negligible importance as a contributor to the intergroup differences in
fibrin clot variables in this case-control study. Thrombin generation as well as coagulation fac-
tors did not differ between the groups. An inverse correlation of clot permeability with tPA:Ag,
which we have reported here, has been observed in previous studies done in subjects without
bleeding tendency [9]. Interestingly, a decreased tPA:Ag level, which represents free tPA and
tPA bound to PAI-1 [24], was an independent predictor of CLT in women with HMB, which is
a novel finding of this study, highlighting a role of this parameter in hemostasis in subjects
with bleeding tendency. Moreover, we demonstrated that patients with HMB had slightly, but
significantly decreased levels of PAI-1:Ag. A very low activity of PAI-1 indicating deficiency of
this inhibitor was shown in case reports describing women with HMB [25]. Slightly lower PAI-
1:Ag might facilitate clot lysis by increasing an active free fraction of tPA in the circulation
Fig 1. ROC curve for tissue plasminogen activator antigen (tPA:Ag). AUC denotes area under curve;
SE, standard error; CI, confidence intervals.
doi:10.1371/journal.pone.0125069.g001
Clot Properties and Excessive Menstruation
PLOS ONE | DOI:10.1371/journal.pone.0125069 April 24, 2015 9 / 14
[24]. Positive correlations between CLT and PAI-1:Ag were reported in healthy subjects or
those with thrombosis or advanced atherosclerosis [21,26], as well as in the study by Wiewel-
Verschuren et al. [22]. We did not observe such association in our patients with HMB. De-
creased levels of tPA:Ag and PAI-1:Ag have already been shown to occur in young women
with a high fibrinolytic potential [27]. Since decreased levels of tPA:Ag and PAI-1:Ag were also
associated with enhanced fibrinolytic activity in our HMB patients as evidenced by shorter
CLT, it might be hypothesized that the net effect of this tPA/PAI-1 pattern leads to reduced in-
hibition of fibrinolysis most likely indicating a potential involvement of endothelial cell dys-
function as the endothelium is a major source of PAI-1 and tPA [24]. Plasma PAP levels, a
sensitive marker of in vivo fibrinolysis, were higher in patients than in the controls, which pro-
vides additional evidence that a hyperfibrinolytic state occurs in the HMB patients.
Regarding routine hemostatic parameters, Knol et al. [28] observed prolonged APTT in
patients with HMB in comparison to the control group. However, we did not show a similar
difference and any alterations in coagulation proteins that determine APTT values. Further
studies are needed to elucidate whether longer APTT occur in women with HMB without
gynaecological abnormalities and known coagulation disorders.
In the context of clot phenotype, of interest is our observation that patients with HMB pre-
sented with a normal, but lower platelet count compared with the well-matched control group.
Several studies demonstrated that platelet activation, reflected by the release a number of sub-
stances, including proteins e.g. platelet factor 4, has been shown to render plasma fibrin clot
properties abnormal with formation of denser networks resistant to enzymatic degradation
[9,17]. Polyphosphate, a polymer of inorganic phosphate secreted by dense granules of activat-
ed platelets, has been demonstrated to unfavorably alter plasma fibrin clot properties, including
Fig 2. ROC curve for clot lysis time (CLT). AUC denotes area under curve; SE, standard error; CI,
confidence intervals.
doi:10.1371/journal.pone.0125069.g002
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plasmin-mediated degradation [29]. Analysis of platelet derived proteins that might affect plas-
ma clot phenotype may increase our knowledge on the links between platelets and fibrin prop-
erties in patients with HMB. From the methodological point of view, assessment of clot lysis
was of particular importance and was performed by means of two assays with the use of various
concentrations of tPA. Given differences in response to tPA while using various assays to assess
clot lysis, reported in several studies [11–12, 17], we provided evidence that CLT with a rela-
tively low final tPA concentration is the preferred approach that may show a subtle modulation
of the fibrinolytic system in women with HMB of unknown cause. At high tPA concentrations,
we observed no intergroup differences in fibrinolysis markers such as the rate of increases in
D-dimer released from plasma clots. We confirmed that assays for measuring fibrinolysis effi-
ciency should be adjusted to a given disease state and one assay is unlikely to be a good ap-
proach for all clinical situations related to hemostatic disorders. The current study had several
Fig 3. Representative SEM images of plasma fibrin clots. (A) a patient with heavy menstrual bleeding
(HMB). (B) a healthy control subject. Magnification 5000x. Scale bar 5 μm.
doi:10.1371/journal.pone.0125069.g003
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limitations. First of all, the number of the women studied was relatively low, though the study
was sufficiently powered to show intergroup differences. Second, all parameters were deter-
mined at a single time point so we cannot exclude a certain variability of fibrin parameters over
time. Third, experiments on purified fibrinogen were not performed. They could have helped
to assess a contribution of posttranslational fibrinogen modification to clot abnormalities re-
ported here. The precise molecular mechanisms underlying abnormal clot phenotype in HMB
remain to be elucidated. We cannot exclude that co-existence of thrombophilia might modify
the bleeding risk and fibrin clot phenotype in this clinical setting [9,30]. Fourth, the measure-
ment of fibrinopeptide A cleavage would be useful in evaluating slower fibrin formation in
HMB patients. This test has not been performed in the current project. Finally, in clinical prac-
tice, like in our study, assessment of abnormal menstrual bleeding is largely based on the pa-
tient’s experience and could be imprecise like data on other bleeding manifestations. Moreover,
several studies have shown that a mere measurement of blood loss does not precisely character-
ize all clinical aspects of excessive menstruation [31–33].
In conclusion, the current study shows that increased clot permeability and susceptibility to
lysis may represent novel characteristics of women aged below 50 years who suffer from HMB
without known organic or hemostatic abnormalities. Our observations suggest that a hemor-
rhagic clot phenotype can be found among subjects with idiopathic bleeding tendency. Larger
groups of patients with HMB are needed to validate our observations and their practical
implications.
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